Elena A. Seregina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elena A. Seregina has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Alexander V. Poletaev
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
29 shared publications - Pavel A. Zharkov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
23 shared publications - Daria V. Fedorova
The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Health of the Russian Federation
17 shared publications - Alexey V. Pshonkin
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
16 shared publications - Mikhail Aleksandrovich Panteleev
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Moscow, Russia
10 shared publications - Nataliya Sergeevna Smetanina
National Scientific and Practical Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Moscow, Russia
8 shared publications
Latest Publications
- Open Access
- 12 August 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (2) , 73-79
Pharmacokinetic parameters and clinical experience with perioperative continuous infusion of coagulation factor VIII and IX concentrates in children with hemophilia A and B
Introduction . Сontinuous infusion of factor concentrate makes it possible to achieve stable activity of the deficient factor over a long period of time and appears to be an attractive alternative to bolus administration of concentrate as part of perioperative prophylaxis. The aim of the study – evaluation of pharmacokinetic parameters when using continuous factor infusion VIII and IX concentrates in children with hemophilia A and B in the perioperative period in real clinical practice. Materials and methods . A retrospective analysis of medical records data from children with hemophilia A and B who underwent surgical treatment with continuous infusion of factor VIII concentrate was performed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology from 2015 to 2024. The following pharmacokinetic parameters were also assessed during administration (ACL TOP 700): activity of factors VIII and IX before the administration of concentrate, 30 min after the administration of the concentrate dose and the start of surgery, at finish of the surgery and also every 24 h from the time of surgery until the factor infusion was stopped (single-stage clotting method for determining HemosIL, Instrumentation Laboratory, USA), activated partial thromboplastin time and thromboelastogram. An assessment of bleeding, the presence of an inhibitor to the factor and thrombosis in the early postoperative period was carried out. Results . The study included 5 patients with hemophilia A and 2 patients with hemophilia B. Before surgery, all patients received bolus infusion at a dose of 1000 to 5000 IU with subsequent transition to continuous factor infusion at a median dose of 5 IU/kg/h (range – 3.5 to 9,0 IU/kg/h). All patients had stable pharmacokinetic parameters; the activity of the deficient factor was in the expected range. No patient had complications of surgery with bleeding or thrombosis. Conclusions . In real clinical practice, when using continuous infusion of factor VIII concentrate at a dose of 3,5–9,0 IU/kg/h, stable pharmacokinetic parameters are achieved, allowing its use in children when planning perioperative management.
- 12 August 2026
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 13 (2) , 73-79
Open AccessPharmacokinetic parameters and clinical experience with perioperative continuous infusion of coagulation factor VIII and IX concentrates in children with hemophilia A and B
Introduction . Сontinuous infusion of factor concentrate makes it possible to achieve stable activity of the deficient factor over a long period of time and appears to be an attractive alternative to bolus administration of concentrate as part of perioperative prophylaxis. The aim of the study – evaluation of pharmacokinetic parameters when using continuous factor infusion VIII and IX concentrates in children with hemophilia A and B in the perioperative period in real clinical practice. Materials and methods . A retrospective analysis of medical records data from children with hemophilia A and B who underwent surgical treatment with continuous infusion of factor VIII concentrate was performed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology from 2015 to 2024. The following pharmacokinetic parameters were also assessed during administration (ACL TOP 700): activity of factors VIII and IX before the administration of concentrate, 30 min after the administration of the concentrate dose and the start of surgery, at finish of the surgery and also every 24 h from the time of surgery until the factor infusion was stopped (single-stage clotting method for determining HemosIL, Instrumentation Laboratory, USA), activated partial thromboplastin time and thromboelastogram. An assessment of bleeding, the presence of an inhibitor to the factor and thrombosis in the early postoperative period was carried out. Results . The study included 5 patients with hemophilia A and 2 patients with hemophilia B. Before surgery, all patients received bolus infusion at a dose of 1000 to 5000 IU with subsequent transition to continuous factor infusion at a median dose of 5 IU/kg/h (range – 3.5 to 9,0 IU/kg/h). All patients had stable pharmacokinetic parameters; the activity of the deficient factor was in the expected range. No patient had complications of surgery with bleeding or thrombosis. Conclusions . In real clinical practice, when using continuous infusion of factor VIII concentrate at a dose of 3,5–9,0 IU/kg/h, stable pharmacokinetic parameters are achieved, allowing its use in children when planning perioperative management.
- Open Access
- 14 April 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (1) , 74-81
Essential thrombocythemia in childhood: features of platelet structure and function
Introduction. Essential thrombocythemia (ET) is an orphan myeloproliferative disease with excessive platelet production associated with an increased risk of thrombosis and bleeding. Currently, there is a limited number of studies on the state of platelet hemostasis in children with ET. Aim of this single-center prospective study was to characterize the morphological and functional properties of platelets in pediatric patients with ET. Materials and methods. The study included 30 patients (10 boys and 20 girls) aged 3–17 years with an established diagnosis of ET. The control group consisted of 45 healthy volunteers (22 boys and 23 girls) aged 4–18 years. Flow cytometry with strong and weak activation, aggregometry, and immunofluorescence microscopy of blood smears were used to analyze platelet function. Results. It was shown that platelets of patients with ET are characterized by a reduced size, while the number of platelet alpha and dense granules did not differ from the control group. Platelets of patients with ET showed moderate hyporeactivity in response to strong stimulation (by activation of glycoprotein IIbIIIa and secretion of dense granules). Platelet aggregation with collagen and adenosine diphosphate was also reduced in patients with ET, but these data did not correlate with the degree of platelet activation in flow cytometry. Conclusion. Thus, characteristic morphological and functional changes in platelets were revealed in children with ET compared with the control group.
- 14 April 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 25 (1) , 74-81
Open AccessEssential thrombocythemia in childhood: features of platelet structure and function
Introduction. Essential thrombocythemia (ET) is an orphan myeloproliferative disease with excessive platelet production associated with an increased risk of thrombosis and bleeding. Currently, there is a limited number of studies on the state of platelet hemostasis in children with ET. Aim of this single-center prospective study was to characterize the morphological and functional properties of platelets in pediatric patients with ET. Materials and methods. The study included 30 patients (10 boys and 20 girls) aged 3–17 years with an established diagnosis of ET. The control group consisted of 45 healthy volunteers (22 boys and 23 girls) aged 4–18 years. Flow cytometry with strong and weak activation, aggregometry, and immunofluorescence microscopy of blood smears were used to analyze platelet function. Results. It was shown that platelets of patients with ET are characterized by a reduced size, while the number of platelet alpha and dense granules did not differ from the control group. Platelets of patients with ET showed moderate hyporeactivity in response to strong stimulation (by activation of glycoprotein IIbIIIa and secretion of dense granules). Platelet aggregation with collagen and adenosine diphosphate was also reduced in patients with ET, but these data did not correlate with the degree of platelet activation in flow cytometry. Conclusion. Thus, characteristic morphological and functional changes in platelets were revealed in children with ET compared with the control group.
- Open Access
- 29 January 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (4) , 161-165
A clinical case of inhibitor development in a patient with type 3 von Willebrand disease and the use of emicizumab as hemostatic treatment
Background. Von Willebrand disease is one of the most common bleeding disorders, with a prevalence ranging from 1 in 100 for asymptomatic disease to 1 in 1000 for severe forms of von Willebrand disease associated with bleeds. The mainstay of therapy for von Willebrand disease is desmopressin and replacement therapy with von Willebrand factor concentrate. One of extremely rare and serious complications of this therapy is the development of an inhibitor to von Willebrand factor. Clinical case. This article describes the clinical presentation, phenotype, and bleeding manifestations in a female patient with von Willebrand disease with inhibitors, as well as our experience of using emicizumab as off-label therapy. Conclusion. The development of an inhibitor in patients with von Willebrand disease is an extremely rare complication; this is the first time that we encountered this complication at our center. Physicians should suspect inhibitor development if standard therapy is ineffective or if a patient develops break-through bleedings or allergic reactions to von Willebrand factor concentrate. The off-label use of emicizumab in these patients can reduce spontaneous bleeding episodes and prevent life-threatening bleeding.
- 29 January 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (4) , 161-165
Open AccessA clinical case of inhibitor development in a patient with type 3 von Willebrand disease and the use of emicizumab as hemostatic treatment
Background. Von Willebrand disease is one of the most common bleeding disorders, with a prevalence ranging from 1 in 100 for asymptomatic disease to 1 in 1000 for severe forms of von Willebrand disease associated with bleeds. The mainstay of therapy for von Willebrand disease is desmopressin and replacement therapy with von Willebrand factor concentrate. One of extremely rare and serious complications of this therapy is the development of an inhibitor to von Willebrand factor. Clinical case. This article describes the clinical presentation, phenotype, and bleeding manifestations in a female patient with von Willebrand disease with inhibitors, as well as our experience of using emicizumab as off-label therapy. Conclusion. The development of an inhibitor in patients with von Willebrand disease is an extremely rare complication; this is the first time that we encountered this complication at our center. Physicians should suspect inhibitor development if standard therapy is ineffective or if a patient develops break-through bleedings or allergic reactions to von Willebrand factor concentrate. The off-label use of emicizumab in these patients can reduce spontaneous bleeding episodes and prevent life-threatening bleeding.
- Open Access
- 29 January 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (4) , 134-142
The role of microparticles in coagulation changes in patients with hereditary spherocytosis
Introduction. Hereditary spherocytosis is a congenital disease the pathogenesis of which is based on the abnormalities of proteins in the erythrocyte membrane, resulting in impaired membrane permeability and elasticity. During the circulation in the blood flow, the surface to volume ratio of the red blood cell is disturbed, and the erythrocyte acquires a spherical shape. After passing through small capillaries, parts of the membrane, microparticles, are “laced off” from the red blood cell. There is a perception that one of the mechanisms of the development of hypercoagulation leading to thromboembolism in patients with hemolysis is the contribution of procoagulant microparticles. Indeed, the microparticles that have separated from the erythrocyte rapidly become adenosine triphosphate-free, resulting in the loss of asymmetric lipid distribution in the microparticle membrane. Phosphatidylserine, a factor important for blood clotting, is exposed on the outside surface of the microparticle. Aim: to investigate microparticles in the patients with hereditary spherocytosis. Materials and methods. Microparticles were assessed using flow cytometry; procoagulant (phosphatidylserine-positive) microparticles were labeled with annexin V, and erythrocyte microparticles were labeled with antibodies to glycophorin A. Coagulation state in the patients was assessed using activated partial thromboplastin time and thrombodynamics. Results. It has been shown that the number of procoagulant microparticles increases during hemolytic crisis in children with hereditary spherocytosis, which leads to hypercoagulation. It was detected using a global hemostasis assay, thrombodynamics. The increased number of microparticles is one of the possible mechanisms underlying blood clotting disorders. At the same time, the procoagulant properties of microparticles isolated from the blood of the patients with spherocytosis did not differ from those of microparticles isolated from the blood of healthy donors. Conclusion. Presumably, an increased number of microparticles can be considered a biomarker of cell damage and prothrombotic conditions.
- 29 January 2026
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (4) , 134-142
Open AccessThe role of microparticles in coagulation changes in patients with hereditary spherocytosis
Introduction. Hereditary spherocytosis is a congenital disease the pathogenesis of which is based on the abnormalities of proteins in the erythrocyte membrane, resulting in impaired membrane permeability and elasticity. During the circulation in the blood flow, the surface to volume ratio of the red blood cell is disturbed, and the erythrocyte acquires a spherical shape. After passing through small capillaries, parts of the membrane, microparticles, are “laced off” from the red blood cell. There is a perception that one of the mechanisms of the development of hypercoagulation leading to thromboembolism in patients with hemolysis is the contribution of procoagulant microparticles. Indeed, the microparticles that have separated from the erythrocyte rapidly become adenosine triphosphate-free, resulting in the loss of asymmetric lipid distribution in the microparticle membrane. Phosphatidylserine, a factor important for blood clotting, is exposed on the outside surface of the microparticle. Aim: to investigate microparticles in the patients with hereditary spherocytosis. Materials and methods. Microparticles were assessed using flow cytometry; procoagulant (phosphatidylserine-positive) microparticles were labeled with annexin V, and erythrocyte microparticles were labeled with antibodies to glycophorin A. Coagulation state in the patients was assessed using activated partial thromboplastin time and thrombodynamics. Results. It has been shown that the number of procoagulant microparticles increases during hemolytic crisis in children with hereditary spherocytosis, which leads to hypercoagulation. It was detected using a global hemostasis assay, thrombodynamics. The increased number of microparticles is one of the possible mechanisms underlying blood clotting disorders. At the same time, the procoagulant properties of microparticles isolated from the blood of the patients with spherocytosis did not differ from those of microparticles isolated from the blood of healthy donors. Conclusion. Presumably, an increased number of microparticles can be considered a biomarker of cell damage and prothrombotic conditions.
- Open Access
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 47-55
The state of the hemostasis system in patients with myeloproliferative neoplasm: primary results
Introduction . Essential thrombocythemia (ET) is a type of clonal myeloproliferative neoplasm, which is characterized by uncontrolled proliferation of megakaryocytes. It is associated with an increased number of large and giant megakaryocytes in the bone marrow, leading to thrombocytosis and a high risk of both thrombosis and bleeding. Unlike in adults, pediatric patients with ET often do not experience any clinical manifestations of the disease. However, based on data from adult studies, it is possible that ET and polycythemia vera in children can also lead to both thrombotic and hemorrhagic complications. Changes in the hemostatic system are an important factor that can contribute to these risks. The aim of this study was to evaluate the state of blood coagulation system in children with thrombocytosis and erythrocytosis using standard coagulation tests, aggregometry, global hemostasis assays, levels of von Willebrand factor antigen (vWF:Ag) and activity and markers of endothelial dysfunction. Materials and methods . Activated partial thromboplastin time, prothrombin time, thrombin time, fibrinogen, antithrombin III, D-dimer, vWF:Ag and activity RCo of von Willebrand factor, platelet aggregation with adenosine diphosphate (ADP), collagen, ristocetin, thromboelastography and thrombodynamics, endothelin-1 and thrombomodulin levels. The concentration of procoagulant micropartocles derived from the patients' plasma was estimated by flow cytometry. 59 patients diagnosed with ET were enrolled in this study. 13 children with secondary thrombocytosis and 23 with erythrocytosis were enrolled as the control groups. Results. The results of routine coagulation tests, as well as measurements of antithrombin III activity, D-dimer levels, vWF:Ag, thrombomodulin and endothelin-1, were within the normal range in most patients. The decrease in platelet aggregation was observed after stimulation with ADP in 29 % of patients, with collagen in 37 %, and with ristocetin in 47 %. A statistically significant correlation was found between the decrease in platelet aggregation and the increase in platelet counts. Increased aggregation was seen with ADP and collagen in only 11 and 18 % of patients, respectively, which may indicate a potential prothrombotic tendency and microcirculatory abnormalities in patients with ET. Acquired von Willebrand syndrome was present in 54 % of patients. Analysis showed that among patients with extreme thrombocytosis (> 1500 × 109/L), all had acquired von Willebrand disease. In addition, in patients with extreme thrombocytosis, there was an increase in parameters of thromboelastography, such as angle α and maximum amplitude, as well as clot growth rates in the thrombodynamics test. Correlation analysis showed significant dependences (p < 0.05) between the parameters of thromboelastography and thromobodynamics on both platelet count and number of procoagulant microvesicles. Conclusions . Despite the differences in clinical manifestations in children with ET, a close correlation has been identified between increased platelet counts and changes in their aggregation function, as well as, between increased platelet counts and changes in global hemostasis assays. All patients with hemorrhagic symptoms had laboratory signs of acquired von Willebrand syndrome.
- 2 November 2025
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (3) , 47-55
Open AccessThe state of the hemostasis system in patients with myeloproliferative neoplasm: primary results
Introduction . Essential thrombocythemia (ET) is a type of clonal myeloproliferative neoplasm, which is characterized by uncontrolled proliferation of megakaryocytes. It is associated with an increased number of large and giant megakaryocytes in the bone marrow, leading to thrombocytosis and a high risk of both thrombosis and bleeding. Unlike in adults, pediatric patients with ET often do not experience any clinical manifestations of the disease. However, based on data from adult studies, it is possible that ET and polycythemia vera in children can also lead to both thrombotic and hemorrhagic complications. Changes in the hemostatic system are an important factor that can contribute to these risks. The aim of this study was to evaluate the state of blood coagulation system in children with thrombocytosis and erythrocytosis using standard coagulation tests, aggregometry, global hemostasis assays, levels of von Willebrand factor antigen (vWF:Ag) and activity and markers of endothelial dysfunction. Materials and methods . Activated partial thromboplastin time, prothrombin time, thrombin time, fibrinogen, antithrombin III, D-dimer, vWF:Ag and activity RCo of von Willebrand factor, platelet aggregation with adenosine diphosphate (ADP), collagen, ristocetin, thromboelastography and thrombodynamics, endothelin-1 and thrombomodulin levels. The concentration of procoagulant micropartocles derived from the patients' plasma was estimated by flow cytometry. 59 patients diagnosed with ET were enrolled in this study. 13 children with secondary thrombocytosis and 23 with erythrocytosis were enrolled as the control groups. Results. The results of routine coagulation tests, as well as measurements of antithrombin III activity, D-dimer levels, vWF:Ag, thrombomodulin and endothelin-1, were within the normal range in most patients. The decrease in platelet aggregation was observed after stimulation with ADP in 29 % of patients, with collagen in 37 %, and with ristocetin in 47 %. A statistically significant correlation was found between the decrease in platelet aggregation and the increase in platelet counts. Increased aggregation was seen with ADP and collagen in only 11 and 18 % of patients, respectively, which may indicate a potential prothrombotic tendency and microcirculatory abnormalities in patients with ET. Acquired von Willebrand syndrome was present in 54 % of patients. Analysis showed that among patients with extreme thrombocytosis (> 1500 × 109/L), all had acquired von Willebrand disease. In addition, in patients with extreme thrombocytosis, there was an increase in parameters of thromboelastography, such as angle α and maximum amplitude, as well as clot growth rates in the thrombodynamics test. Correlation analysis showed significant dependences (p < 0.05) between the parameters of thromboelastography and thromobodynamics on both platelet count and number of procoagulant microvesicles. Conclusions . Despite the differences in clinical manifestations in children with ET, a close correlation has been identified between increased platelet counts and changes in their aggregation function, as well as, between increased platelet counts and changes in global hemostasis assays. All patients with hemorrhagic symptoms had laboratory signs of acquired von Willebrand syndrome.
- 11 August 2025
- Published by ECO-Vector LLC in Russian Pediatric Ophthalmology
- Vol. 20 (2) , 146-153
The role of platelets in retinopathy of prematurity
The review discusses the factors affecting the development of retinopathy of prematurity, namely, the role of low platelet count in the pathogenesis of the disease and association with its severe forms. Recently, platelets have been revealed to play a key role in angiogenesis and the delivery of regulatory proteins. This pathogenetic association may be attributed to two factors. Firstly, children with retinopathy of prematurity and low platelet count develop disrupted delivery of regulatory proteins necessary to maintain optimal platelet count. Secondly, excess vascular endothelial growth factor A is absorbed incompletely, which contributes to overstimulation of endothelial cells, their proliferation, and hence retinopathy of prematurity. Thus, the main pathogenetic mechanisms of platelet count effect on the development of retinopathy of prematurity may be associated with the fact that they locally stimulate or inhibit angiogenesis. Low platelet count in peripheral blood slows down normal vasculogenesis of the peripheral retina. However, platelet transfusions and partial hemolysis result in release of bioactive substances regulating angiogenesis, including vascular endothelial growth factor and hypoxia Inducible factor, from platelet granules, which leads to abnormal vasoproliferation. That is why further studies of platelet count management are warranted to determine the preferred timing and quantities of infusion therapy, which can provide clinical benefit. The need for platelet transfusion in patients with retinopathy of prematurity and thrombocytopenia is still a matter for discussion.
- 11 August 2025
- Published by ECO-Vector LLC in Russian Pediatric Ophthalmology
- Vol. 20 (2) , 146-153
The role of platelets in retinopathy of prematurity
The review discusses the factors affecting the development of retinopathy of prematurity, namely, the role of low platelet count in the pathogenesis of the disease and association with its severe forms. Recently, platelets have been revealed to play a key role in angiogenesis and the delivery of regulatory proteins. This pathogenetic association may be attributed to two factors. Firstly, children with retinopathy of prematurity and low platelet count develop disrupted delivery of regulatory proteins necessary to maintain optimal platelet count. Secondly, excess vascular endothelial growth factor A is absorbed incompletely, which contributes to overstimulation of endothelial cells, their proliferation, and hence retinopathy of prematurity. Thus, the main pathogenetic mechanisms of platelet count effect on the development of retinopathy of prematurity may be associated with the fact that they locally stimulate or inhibit angiogenesis. Low platelet count in peripheral blood slows down normal vasculogenesis of the peripheral retina. However, platelet transfusions and partial hemolysis result in release of bioactive substances regulating angiogenesis, including vascular endothelial growth factor and hypoxia Inducible factor, from platelet granules, which leads to abnormal vasoproliferation. That is why further studies of platelet count management are warranted to determine the preferred timing and quantities of infusion therapy, which can provide clinical benefit. The need for platelet transfusion in patients with retinopathy of prematurity and thrombocytopenia is still a matter for discussion.
- Open Access
- 30 June 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (2) , 74-79
Hereditary factor XIII deficiency in children: diagnostic and clinical features and clinical experience with replacement therapy
Factor XIII deficiency is an extremely rare bleeding disorder with a prevalence of 1 in 2–3 millions. This deficiency is characterized by severe bleeding manifestations: life-threatening bleeding, including recurrent bleeding into the central nervous system. Here, we report 16 cases of factor XIII deficiency in children who were under our observation at the beginning of 2025. The use of factor XIII concentrate is a global standard for the treatment of patients with factor XIII deficiency. Since 2023, children with confirmed hereditary factor XIII deficiency have been receiving this concentrate with the help of the Circle of Kindness Foundation. By the time of publication, 9 out of 12 children who had been prescribed treatment with factor XIII concentrate started to receive it. All the patients receiving this therapy do not have spontaneous bleeding. In this article, we describe clinical and phenotypical features as well as bleeding manifestations in the patients with factor XIII deficiency and present our experience with factor XIII concentrate therapy. Ethical approval was not required since the study involved the use of anonymized retrospective data obtained during routine clinical practice.
- 30 June 2025
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (2) , 74-79
Open AccessHereditary factor XIII deficiency in children: diagnostic and clinical features and clinical experience with replacement therapy
Factor XIII deficiency is an extremely rare bleeding disorder with a prevalence of 1 in 2–3 millions. This deficiency is characterized by severe bleeding manifestations: life-threatening bleeding, including recurrent bleeding into the central nervous system. Here, we report 16 cases of factor XIII deficiency in children who were under our observation at the beginning of 2025. The use of factor XIII concentrate is a global standard for the treatment of patients with factor XIII deficiency. Since 2023, children with confirmed hereditary factor XIII deficiency have been receiving this concentrate with the help of the Circle of Kindness Foundation. By the time of publication, 9 out of 12 children who had been prescribed treatment with factor XIII concentrate started to receive it. All the patients receiving this therapy do not have spontaneous bleeding. In this article, we describe clinical and phenotypical features as well as bleeding manifestations in the patients with factor XIII deficiency and present our experience with factor XIII concentrate therapy. Ethical approval was not required since the study involved the use of anonymized retrospective data obtained during routine clinical practice.
- Open Access
- 13 December 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (4) , 62-70
Diagnosis of type 2B von Willebrand disease in children
Even though von Willebrand disease (vWD) is a common bleeding disorder, it comprises some rare types as well. Type 2B vWD is usually diagnosed in 3-5% of all vWD cases. The important diagnostic markers of this disease subtype include thrombocytopenia, decreased von Willebrand factor (vWF) activity, increased low-dose ristocetin-induced platelet aggregation, and identification of mutations in exon 28 of the vWF gene. The purpose of this study was to highlight challenges associated with the differential diagnosis of vWD as well as to demonstrate heterogeneous clinical and laboratory signs of type 2B vWD. Here, we retrospectively analyzed all the cases of type 2B vWD diagnosed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. For the analysis, we used de-identified data collected during routine clinical care and hence did not need an approval from the Local Ethics Committee. All the patients had undergone medical history assessment and laboratory investigations and had been evaluated for bleeding disorders using the Pediatric Bleeding Questionnaire. Type 2B vWD was diagnosed based on the following criteria: bleeding symptoms, thrombocytopenia, significantly decreased vWF ristocetin-cofactor activity, normal or decreased vWF antigen levels, ristocetin-cofactor activity/vWF antigen ratio 0.7; increased low-dose ristocetin-induced platelet aggregation. Type 2B vWD was diagnosed in 7 patients. Out of these, 5 had bleeding symptoms and 2 had a family history of vWD. All the children had been diagnosed with thrombocytopenia during their first year of life. Five patients had been initially diagnosed with immune thrombocytopenia, with one girl having a family history of vWD. All the patients with diagnosed immune thrombocytopenia had been treated with intravenous immunoglobulins, and one child had also undergone treatment with corticosteroids. Three patients had had to be admitted to hospital for major bleeding before they were diagnosed with vWD. All the patients had the typical laboratory phenotype, and five out of them demonstrated decreased vWF collagen-binding activity. In two patients with positive family history, the diagnosis was genetically verified, with both of them harboring mutations in exons 20 and 28 of the vWF gene. Our findings are consistent with the literature suggesting how challenging differential diagnosis of this vWD type is. Still, a low-dose ristocetin-induced platelet aggregation test along with other laboratory investigations can be used to effectively identify the type 2B vWD phenotype. In Russia, factor replacement therapy remains the primary treatment option for patients with any type of vWD.
- 13 December 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (4) , 62-70
Open AccessDiagnosis of type 2B von Willebrand disease in children
Even though von Willebrand disease (vWD) is a common bleeding disorder, it comprises some rare types as well. Type 2B vWD is usually diagnosed in 3-5% of all vWD cases. The important diagnostic markers of this disease subtype include thrombocytopenia, decreased von Willebrand factor (vWF) activity, increased low-dose ristocetin-induced platelet aggregation, and identification of mutations in exon 28 of the vWF gene. The purpose of this study was to highlight challenges associated with the differential diagnosis of vWD as well as to demonstrate heterogeneous clinical and laboratory signs of type 2B vWD. Here, we retrospectively analyzed all the cases of type 2B vWD diagnosed at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology. For the analysis, we used de-identified data collected during routine clinical care and hence did not need an approval from the Local Ethics Committee. All the patients had undergone medical history assessment and laboratory investigations and had been evaluated for bleeding disorders using the Pediatric Bleeding Questionnaire. Type 2B vWD was diagnosed based on the following criteria: bleeding symptoms, thrombocytopenia, significantly decreased vWF ristocetin-cofactor activity, normal or decreased vWF antigen levels, ristocetin-cofactor activity/vWF antigen ratio 0.7; increased low-dose ristocetin-induced platelet aggregation. Type 2B vWD was diagnosed in 7 patients. Out of these, 5 had bleeding symptoms and 2 had a family history of vWD. All the children had been diagnosed with thrombocytopenia during their first year of life. Five patients had been initially diagnosed with immune thrombocytopenia, with one girl having a family history of vWD. All the patients with diagnosed immune thrombocytopenia had been treated with intravenous immunoglobulins, and one child had also undergone treatment with corticosteroids. Three patients had had to be admitted to hospital for major bleeding before they were diagnosed with vWD. All the patients had the typical laboratory phenotype, and five out of them demonstrated decreased vWF collagen-binding activity. In two patients with positive family history, the diagnosis was genetically verified, with both of them harboring mutations in exons 20 and 28 of the vWF gene. Our findings are consistent with the literature suggesting how challenging differential diagnosis of this vWD type is. Still, a low-dose ristocetin-induced platelet aggregation test along with other laboratory investigations can be used to effectively identify the type 2B vWD phenotype. In Russia, factor replacement therapy remains the primary treatment option for patients with any type of vWD.
- Open Access
- 13 December 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (4) , 112-118
Five-year experience in remote diagnosis of von Willebrand disease in Russia
Accurate and timely laboratory diagnosis plays a key role in specifying the causes of hemorrhagic events both in children and adults. However, due to the rarity and diversity of some bleeding disorders, a full spectrum of laboratory testing may not be available in certain regions or hospitals. Taking into account these limitations, a programme of remote diagnosis of von Willebrand disease (VWD) was initiated in 2019. The aim of our study was to assess the results of the programme. In accordance with the study protocol, peripheral blood samples from patients suspected of VWD were collected at local healthcare facilities and, after initial sample preparation, were transferred to the Laboratory of Clinical Hemostasis of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Ethical approval was not required since the study only involved the use of anonymized and generalized retrospective data obtained during routine clinical practice. Coagulation analysis included tests for von Willebrand factor antigen (vWF:Ag), von Willebrand factor ristocetin cofactor activity (vWF:RCo), and factor VIII (FVIII) clotting activity. From 04 November 2019 to 31 December 2023, we received a total of 512 frozen samples from 375 children aged under 18 years (the mean age was 10 years (1 month – 17 years)) and 139 adult patients (the mean age was 35 (18–72) years) from 21 regions of the Russian Federation. Pre-analytical errors were identified in 42 (8.2%) cases. Decreased vWF activity (< 50%) was found in 125 (26.6%) patients. VWF activity < 30% was registered in 52 (11.1%) patients, while vWF:RCo < 50% and > 30% – in 73 (15.5%) cases. In 68 (54.4%) patients, laboratory findings were consistent with vWD type 1, in 50 (40%) cases testing results were indicative of vWD type 2, and 7 (5.6%) patients had vWD type 3. Thirty (6.4%) patients had decreased FVIII/vWF:Ag ratio. Type 2N VWD was found in one woman with low FVIII activity (the FVIII binding activity of VWF was 2%, normal range: 70–130%). The implementation of this programme has allowed us to specify a diagnosis in 125 patients without their in-person presence and regardless of their place of residence. This expands our possibilities of detecting VWD in patients living in regions with limited diagnostic capacity.
- 13 December 2024
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 23 (4) , 112-118
Open AccessFive-year experience in remote diagnosis of von Willebrand disease in Russia
Accurate and timely laboratory diagnosis plays a key role in specifying the causes of hemorrhagic events both in children and adults. However, due to the rarity and diversity of some bleeding disorders, a full spectrum of laboratory testing may not be available in certain regions or hospitals. Taking into account these limitations, a programme of remote diagnosis of von Willebrand disease (VWD) was initiated in 2019. The aim of our study was to assess the results of the programme. In accordance with the study protocol, peripheral blood samples from patients suspected of VWD were collected at local healthcare facilities and, after initial sample preparation, were transferred to the Laboratory of Clinical Hemostasis of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Ethical approval was not required since the study only involved the use of anonymized and generalized retrospective data obtained during routine clinical practice. Coagulation analysis included tests for von Willebrand factor antigen (vWF:Ag), von Willebrand factor ristocetin cofactor activity (vWF:RCo), and factor VIII (FVIII) clotting activity. From 04 November 2019 to 31 December 2023, we received a total of 512 frozen samples from 375 children aged under 18 years (the mean age was 10 years (1 month – 17 years)) and 139 adult patients (the mean age was 35 (18–72) years) from 21 regions of the Russian Federation. Pre-analytical errors were identified in 42 (8.2%) cases. Decreased vWF activity (< 50%) was found in 125 (26.6%) patients. VWF activity < 30% was registered in 52 (11.1%) patients, while vWF:RCo < 50% and > 30% – in 73 (15.5%) cases. In 68 (54.4%) patients, laboratory findings were consistent with vWD type 1, in 50 (40%) cases testing results were indicative of vWD type 2, and 7 (5.6%) patients had vWD type 3. Thirty (6.4%) patients had decreased FVIII/vWF:Ag ratio. Type 2N VWD was found in one woman with low FVIII activity (the FVIII binding activity of VWF was 2%, normal range: 70–130%). The implementation of this programme has allowed us to specify a diagnosis in 125 patients without their in-person presence and regardless of their place of residence. This expands our possibilities of detecting VWD in patients living in regions with limited diagnostic capacity.
- 22 October 2024
- Published by Springer Nature in International Journal of Hematology
- Vol. 120 (6) , 717-724
Assay variables and early clinical evaluation of low-angle light scattering for platelet function analysis
Introduction The recently developed platelet aggregation technique based on low-angle light scattering (LaSca) in diluted platelet-rich plasma (PRP) requires only a small sample volume and provides information about platelet aggregation and shape change. This study aimed to investigate the influence of preanalytical and analytical variables and to validate the method in a real-life pediatric hematology hospital setting. Methods Platelet aggregation was induced by ADP in diluted PRP in the presence of 2 mM calcium at 23 °C. The study included healthy adults (n = 30), healthy children (n = 20), and pediatric patients with suspected or diagnosed platelet function abnormalities (n = 25). Results The assay parameters were stable for at least 3 h after isolation of PRP and were sensitive to plasma dilution in the range of 2–8%. The initial aggregation velocity was significantly reduced in pediatric patients compared with healthy children (p < 0.05). ADP-induced light transmission amplitude was moderately correlated with LaSca amplitude of aggregation in healthy children (p = 0.52, p < 0.05) but not in pediatric patients. Conclusions We standardized the protocol for platelet aggregation assessment by LaSca and characterized the influence of preanalytical and analytical variables on it.
- 22 October 2024
- Published by Springer Nature in International Journal of Hematology
- Vol. 120 (6) , 717-724
Assay variables and early clinical evaluation of low-angle light scattering for platelet function analysis
Introduction The recently developed platelet aggregation technique based on low-angle light scattering (LaSca) in diluted platelet-rich plasma (PRP) requires only a small sample volume and provides information about platelet aggregation and shape change. This study aimed to investigate the influence of preanalytical and analytical variables and to validate the method in a real-life pediatric hematology hospital setting. Methods Platelet aggregation was induced by ADP in diluted PRP in the presence of 2 mM calcium at 23 °C. The study included healthy adults (n = 30), healthy children (n = 20), and pediatric patients with suspected or diagnosed platelet function abnormalities (n = 25). Results The assay parameters were stable for at least 3 h after isolation of PRP and were sensitive to plasma dilution in the range of 2–8%. The initial aggregation velocity was significantly reduced in pediatric patients compared with healthy children (p < 0.05). ADP-induced light transmission amplitude was moderately correlated with LaSca amplitude of aggregation in healthy children (p = 0.52, p < 0.05) but not in pediatric patients. Conclusions We standardized the protocol for platelet aggregation assessment by LaSca and characterized the influence of preanalytical and analytical variables on it.